XBB.1.5 COVID-19 Vaccine’s Surprising Impact on Hospitalizations! Exclusive Study Unveils Unbelievable Results in the Netherlands 2023 – A Must-Read Breakdown!”
In a recent investigation published on the XBB.1.5 COVID-19 medRxiv pre-print server, a group of researchers conducted an assessment of the XBB.1.5 coronavirus disease 2019 (COVID-19) vaccine’s efficacy in diminishing hospitalizations and Intensive Care Unit (ICU) admissions among individuals aged 60 and above who had previously received vaccinations in the Netherlands from October to December 2023.
READ: How Global Leaders Are Secretly Preparing for ‘Disease X’!
The study, titled “Early COVID-19 Vaccine Effectiveness of XBB.1.5 Vaccine against Hospitalization and ICU Admission, the Netherlands, 9 October – 5 December 2023,” emphasizes the preliminary nature of the findings. It is crucial to note that medRxiv publishes preliminary scientific reports that are not peer-reviewed and should not be considered conclusive or guide clinical practice/health-related behavior.
XBB.1.5 COVID-19
In 2023, the Netherlands initiated its seasonal COVID-19 vaccination campaign on October 2, targeting individuals aged 60 and older, healthcare workers, pregnant women, and those with medical risks, utilizing the XBB1.5 Comirnaty vaccine. The study period spanned from early October to late November, during which personal vaccination invitations were sent to residents aged 60 and above. As of early December, 42.9% of this demographic had received vaccination, with the campaign scheduled to continue until the end of December. Continued research is imperative to comprehend the long-term effectiveness of the XBB.1.5 COVID-19 vaccine on hospitalization and ICU admission rates, especially as more data becomes available post-December 2023.
Study Overview:
The research team employed a screening method to evaluate vaccine effectiveness (VE) during the 2023 seasonal COVID-19 vaccination among individuals aged 60 and older in the Netherlands who had previously received at least one COVID-19 vaccination. Hospitalization data, covering the period from October 9 to December 5, 2023, were obtained from the National Institute for Health and Care Excellence (NICE) COVID-19 database on December 11, 2023. This dataset represented approximately 55% of all COVID-19 hospitalizations in the Netherlands during the study period.
The logistic regression model estimated VE and its 95% confidence intervals. VE against hospitalization was found to be 70.7% (CI, 66.6 to 74.3), while VE against ICU admission was approximately 73.3% (CI 42.2 to 87.6). The study revealed a higher VE for individuals aged 75 and older compared to the 60-74 age group. Notably, the VE estimates for the 2023 seasonal campaign were slightly higher than those of the previous fall campaign for individuals aged 60-79.
Limitations and Considerations:
The study acknowledged certain limitations, including the inability to adjust for comorbidities, potential underestimation of VE due to early vaccine recipients’ frailty, and potential overestimation due to a healthy vaccine bias. Additionally, variations in the time since the last booster dose between those who received the 2023 vaccine and those who did not might have impacted VE estimates.
It’s crucial to interpret these findings cautiously, considering the study’s limitations and the evolving nature of the COVID-19 situation. Further research and ongoing monitoring are essential to comprehensively understand the vaccine’s effectiveness over time.
